Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.Results suggest that nuclear GSK-3β ...
Preview this article 1 min Madrigal Pharmaceuticals is moving to a new 54,000-square-foot headquarters as its workforce nears ...
The combination was well tolerated: no treatment-related deaths occurred, and only 6% (2 patients) were discontinued due to ...
GSK has now taken over the entirety of 200 CambridgePark Drive, a six-story building that will eventually house about 400 ...
Motif ? one of the clinical trial technology market's fastest growing companies ? continues contributing to major innovations in how clinical trial patient data are collected, with Chief Scientific ...
hubXchange’s Antibody Therapeutics Xchange Boston 2026 brings together senior-level scientists, R&D leaders, and executives ...
We found that one-third of pharmaceutical companies proactively released the launch price of their medications between 2022 and 2024, and another third released them reactively. Smaller public ...
JPMorgan Chase & Co.’s global co-head of health-care investment banking Ben Carpenter has left the firm for a role at ...
Ohio-based Welltower acquired adjacent senior housing centers for a total of $140M, the Boston Business Journal reported. The ...
Former Nimbus Therapeutics CEO brings proven expertise scaling platform biotech companies and executing key strategic partnerships as Strand advances its clinical pipeline. BOSTON ...
Flagship Pioneering, led by Moderna’s co-founder, has launched scores of new companies — but first, it tries to kill them.
New Jersey’s Innovation Evergreen Fund invests $6.2M in three startups to strengthen the state's innovation economy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback